NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease ...

A webcast and replay of the presentations will be available on Alignment’s investor relations website at https://ir.alignmenthealth.com/.

Safety Shot, Inc. (Nasdaq: SHOT) ("Safety Shot" or the "Company"), a leading wellness and dietary supplement company, today announces the appointment of CORE IR & PR, a leading investor relations, ...

This milestone follows the successful IRB approval, pilot testing and evaluation of Nexalin’s Halo technology at UCSD. The study will evaluate Nexalin’s proprietary Deep Intracranial Frequency ...

CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.

If approved, this off-the-shelf, fixed-duration Columvi combination will be the first bispecific antibody regimen available for patients with DLBCL following relapse ...

Investors interested in participating in the live call can dial: A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the ...

Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

The collaboration is to be carried out through Chartwell Medical’s subsidiaries, including Fuluo (Shanghai) Medical Equipment Co., Ltd., Fuying (Shanghai) Medical Equipment Co., Ltd. (“Fuying”), and ...

Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care ...

In December 2024, Praxis received Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for relutrigine for Dravet Syndrome. This is the third RPDD for relutrigine ...